Trevena Inc TRVN

Healthcare Biotechnology

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

OTCPK:TRVN - Post by User

Trevena Inc

Bullboard Posts

Post by peak2peakon Feb 15, 2017 11:47am

74 Views

Post# 25849245

ATHENA??????(OMG)

Looks interesting GG. Will do some due on this and I note that institutional holders have 63.5% of the company float according to one source I looked at. Not to be too superstitious but I see that the Jan 4/17 NR from Trevena refers to the Phase 3 ATHENA safety study.

The name ATHENA associated with a major development project didn't work out so well for us former IAE holders.

Technically speaking I see the cup with handle completion and today's test of $7. I will give it a few more days to see if $7 holds.

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide